Alpha-antitrypsin - PPL Therapeutics

Drug Profile

Alpha-antitrypsin - PPL Therapeutics

Alternative Names: AAT - PPL Therapeutics; Alpha-1 proteinase inhibitor - PPL Therapeutics; Alpha-1-antitrypsin - PPL Therapeutics; rAAT - PPL Therapeutics; recAAT - PPL Therapeutics; Recombinant AAT; TgAAT - PPL Therapeutics

Latest Information Update: 22 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PPL Therapeutics PLC
  • Developer Bayer; PPL Therapeutics PLC
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Leucocyte elastase inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Alpha 1-antitrypsin deficiency; Cystic fibrosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jul 2003 Suspended - Clinical-Phase-Unknown for Alpha 1-antitrypsin deficiency in United Kingdom (IV)
  • 10 Jul 2003 Suspended - Phase-II for Alpha 1-antitrypsin deficiency in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top